<DOC>
	<DOCNO>NCT02541604</DOCNO>
	<brief_summary>This early phase , multicenter , open-label , single-arm study evaluate safety , tolerability , pharmacokinetics , immunogenicity , preliminary efficacy atezolizumab pediatric young adult participant solid tumor prior treatment proven ineffective .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Immunogenicity , Preliminary Efficacy Atezolizumab ( Anti-Programmed Death-Ligand 1 PD-L1 Antibody ) Pediatric Young Adult Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pediatric solid tumor ( include Hodgkin 's NonHodgkin 's lymphoma ) , prior treatment proven ineffective ( , relapse refractory ) intolerable Disease measurable define RECIST v1.1 , mINRC , Revised Response Criteria Malignant Lymphoma , RANO criterion ( appropriate ) evaluable nuclear medicine technique , immunocytochemistry technique , tumor marker , reliable measure Archival tumor tissue block 15 freshly cut , unstained , serial slide available submission , willingness undergo core excisional biopsy prior enrollment ( fineneedle aspiration , brush biopsy , lavage sample acceptable ) . Participants few 15 slide available may eligible study entry follow discussion Medical Monitor Lansky Performance Status ( participant less [ &lt; ] 16 year old ) Karnofsky Performance Status ( participant great equal [ &gt; = ] 16 year old ) &gt; =50 Life expectancy &gt; =3 month , investigator 's judgment Adequate hematologic end organ function , confirm laboratory result obtain within 28 day prior initiation study drug Known primary central nervous system ( CNS ) malignancy symptomatic CNS metastasis , except ATRT Treatment highdose chemotherapy hematopoietic stemcell rescue within 3 month prior initiation study drug Prior allogeneic hematopoietic stemcell transplantation prior solidorgan transplantation Treatment chemotherapy ( highdose chemotherapy describe ) differentiation therapy ( retinoic acid ) immunotherapy ( antiGD2 antibody treatment ) within 3 week prior initiation study drug , treatment include nitrosoureas , within 6 week prior initiation study drug Treatment thoracic mediastinal radiotherapy within 3 week prior initiation study drug Treatment hormonal therapy ( except hormone replacement therapy oral contraceptive ) biologic therapy within 4 week 5 halflives , whichever short , prior initiation study drug . This requirement may waive investigator 's request participant recover therapeutic toxicity degree specify protocol , approval Medical Monitor Treatment longacting hematopoietic growth factor within 2 week prior initiation study drug shortacting hematopoietic growth factor within 1 week prior initiation study drug Treatment investigational therapy ( exception cancer therapy describe ) within 4 week prior initiation study drug Treatment live vaccine live , attenuated vaccine ( e.g. , nasal spray live attenuate influenza vaccine FluMistÂ® ) within 4 week prior initiation study drug anticipation treatment require study within 5 month final dose study drug Treatment herbal cancer therapy within 1 week prior initiation study drug Prior treatment cluster differentiation 137 ( CD137 ) agonists immune checkpoint blockade therapy , include anticytotoxic Tlymphocyteassociated protein 4 ( antiCTLA4 ) , antiprogrammed death1 ( PD1 ) , antiPDL1 therapeutic antibody Treatment systemic immunostimulatory agent ( include limit interferon interleukin 2 [ IL2 ] ) within 6 week five drug elimination halflives prior Day 1 Cycle 1 , whichever longer Treatment systemic corticosteroid systemic immunosuppressive medication ( include limit prednisone , dexamethasone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ TNF ] agent ) time initiation study drug , anticipate requirement systemic immunosuppressive medication study Current treatment therapeutic anticoagulant Any nonhematologic toxicity ( exclude alopecia ) prior treatment resolve Grade less equal ( &lt; = ) 1 ( per National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] version 4.0 ) screen Known hypersensitivity biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>